NSE · PPLPHARMA
Piramal Pharma Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹1,345 Cr with net profit ₹171 Cr — a 12.69% net margin, versus 10.09% the period before.
Shareholding
As of 2026-09-30
- Promoter34.8%
- Public37.11%
- FII13.65%
- DII14.44%
4,13,197 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.84× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #17 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,46,276 Cr | 36.26 | 5 | 13.79% | 17.89% |
| Laurus Labs Limited | ₹1,26,433 Cr | 94.35 | 20.82 | 22.11% | 17.13% |
| Zydus Lifesciences Ltd. | ₹1,19,491 Cr | 26.29 | 4.29 | 15.1% | 14.11% |
| Dr Reddys Laboratories Ltd. | ₹1,14,683 Cr | 40.96 | 2.95 | 7.21% | 8.49% |
| Cipla Ltd. | ₹1,13,991 Cr | 36.71 | 3.22 | 8.18% | 10.39% |
| Mankind Pharma Limited | ₹1,04,913 Cr | 44.96 | 5.97 | 12.76% | 14.58% |
| Aurobindo Pharma Ltd. | ₹1,03,568 Cr | 25.52 | 2.62 | 10.13% | 10.88% |
| Lupin Limited | ₹90,914 Cr | 16.14 | 3.78 | 21.65% | 17.07% |
| Glenmark Pharmaceuticals Ltd. | ₹73,096 Cr | 23.42 | 6.53 | 18.07% | 9.22% |
| Alkem Laboratories Ltd. | ₹63,334 Cr | 27.79 | 4.56 | 16.66% | 14.31% |
| Piramal Pharma Limited(this company) | ₹31,862 Cr | — | 3.91 | -78.97% | -2.14% |
AI analysis
AI-generated · google/gemini-2.5-flashPiramal Pharma Limited is listed with a market capitalization of Rs 23814 Cr. The company reported revenue of Rs 9082.38 Cr and a negative profit margin of -367.5%. Its return on equity (ROE) was -357.6%, and return on capital employed (ROCE) was 2.5789%.
Positives
- +Revenue grew by 12% to Rs 9082.38 Cr.
- +Debt-to-equity ratio is 0.65.
- +Promoter pledge is 0% of their holding.
- +Institutions held 27.0905% of shares as of June 2026.
Negatives
- −The company reported a negative profit margin of -367.5%.
- −Return on equity (ROE) is significantly negative at -357.6%.
- −The latest annual net profit for March 2026 was -325.94 Cr, with EPS at -2.46.
- −FII shareholding decreased from 32.226% in August 2023 to 12.5162% in June 2026.
- −Quarterly net profit was -8.83 Cr for March 2026.
Financial Performance
Piramal Pharma Limited generated revenue of Rs 9082.38 Cr, marking a 12% revenue growth. However, the company recorded a negative profit margin of -367.5%. The annual net profit for March 2026 was -325.94, with basic EPS at -2.46 for the same period. More recently, for the quarter ending March 2026, the company reported revenue of Rs 2751.77 Cr and a net profit of -8.83.
Profitability & Returns
The company's profitability metrics show a Negative return on equity (ROE) of -357.6%. The return on capital employed (ROCE) stands at 2.5789%. The profit margin was significantly negative at -367.5%, indicating that the company is incurring substantial losses relative to its revenue.
Balance Sheet
Piramal Pharma Limited has a debt-to-equity ratio of 0.65. The book value per share is Rs 61.34. Further details regarding other balance sheet components are not provided.
Ownership & Pledges
As of June 30, 2026, promoter shareholding was 34.8012%, with DII holding 14.5743% and FII holding 12.5162%. Public shareholding was 38.1083%. There are no promoter shares pledged. The total number of shareholders stood at 461096.
Shareholding Changes
Promoter shareholding in Piramal Pharma Limited has shown minor fluctuations, from 35.0233% in August 2023 to 34.8012% by June 2026. FII holding has decreased from 32.226% in August 2023 to 12.5162% in June 2026. DII holding increased from 7.8257% to 14.5743% over the same period. Public shareholding has increased from 24.925% to 38.1083%.
Data as of — price: 2026-11-07 · financials: Sep 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.